Abstract 25P
Background
Epithelial ovarian cancer (EOC) is a disease found mainly in advanced stages and difficult to treat. The study of the expression and methylation of miRNA genes can become the basis for the development of potential new diagnostic and prognostic markers of EOC, as well as the basis for the development of targeted anticancer therapy.
Methods
80 paired samples of EOC (ovarian serous adenocracinoma) were obtained from the National Medical Research Center of Oncology named after N.N. Blokhin. MicroRNA expression was assessed by TaqMan-qPCR with kits from Applied Biosystems, USA. Analysis of methylation of promoter CpG islands of microRNA genes was carried out using bisulfite conversion followed by methyl-specific PCR.
Results
The methylation frequency in the tumor was higher than in paired norm for 10 microRNA genes (MIR-124-1, -124-2, -124-3, -125B-1, -127, -129-2, -132, -137, -193A and -339; p ≤ 5×10-4). ROC analysis showed that a combination of 4 microRNA genes (MIR-124-2, -127, -129-2, -137) can be proposed as a panel of EOC detection markers with sensitivity (Sn) 80%, specificity (Sp) 82 %, AUC=0.86. The combination of miRNA genes (MIR-193A, -129-2, -137) was characterized by Sn=90%, Sp=75% and AUC=0.90. For 5 out of 12 microRNAs studied, a high frequency of reduced expression was observed: miR-125b-5p - in 59% of tumor samples compairing to paired norms, miR-129-5p - in 55%, miR-132-3p - in 55%, miR-137 - in 52% , and miR-193a-5p in 66% (p ≤ 0.05). The correlation of changes in the expression of 12 microRNAs (miR-124-3p, -125b-5p, -127-5p, 129-5p, -132-3p, -137, -148a-3p, -191-5p, -193a-5p, -203a, -339-3p and -375) and changes in methylation of the genes encoding them rs=0.67-0.97 (according to Spearman), p ≤ 10-4.
Conclusions
The role of methylation in the regulation of the expression of 12 microRNAs and the association of the methylation status of 10 microRNA genes with EOC metastasis were revealed. 5 microRNAs downregulated by hypermethylation may find use as potential targets for EOC therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The state task FGFU-2022-0007 of the Ministry of Science and Higher Education of the Russian Federation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
Presenter: Brian Van Tine
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
Presenter: Nadezhda Knauer
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
Presenter: Alexander Sultanbaev
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Presenter: Gulsah Nomak
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
Presenter: Samart Phuwapraisirisan
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
Presenter: Vito Spataro
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
Presenter: Ryuk Jun Kwon
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
Presenter: Masato Inazu
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers influences apoptosis and proliferations of NSCLC cells
Presenter: Mateusz Iwanski
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Censoring imbalance in ACIS trial for prostate cancer
Presenter: Noa Zimhony-Nissim
Session: Cocktail & Poster Display session
Resources:
Abstract